CD274 and neoplasm: To date, the majority of immunotherapies have focused on reversing T-cell exhaustion to attack tumour cells, including immune checkpoint inhibitors (ICIs) targeting the programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) axis.